Key warning signs include: Discolouration : Most GLP-1 solutions should be clear and colourless or slightly yellowish (depending on the product)
This overlap is not inherently dangerous, but it means you are effectively on a dual medication regimen during the transition, which can amplify side effects
Tirzepatide 5, 10, 15 mg produced roughly 16 to 22.5 percent losses over 72 weeks in the SURMOUNT-1 trial, with more loss at higher doses
Practical consideration: Liposomal formulations are typically more expensive
Trulicity (dulaglutide) is a GLP-1 receptor agonist manufactured by Eli Lilly: FDA approval: 2014 for Type 2 diabetes Dosing: Weekly subcutaneous injection (0.75mg, 1.5mg, 3.0mg, or 4.5mg) Device: Single-use, disposable pen with hidden needle Mechanism: Activates GLP-1 receptors to improve blood sugar control and reduce appetite Trulicity was one of the earlier weekly GLP-1 medications and gained popularity partly due to its user-friendly injection device